• Company
• Will Piqray benefit be successful again?
• by Eo, Yun-Ho Feb 16, 2023 05:50am

• Company
• Astellas Korea appoints Junil Kim as new head
• by Eo, Yun-Ho Feb 15, 2023 05:59am

• Company
• Dementia with Lewy bodies rises as a new blue ocean
• by Feb 15, 2023 05:58am

• Company
• GSK immuno-cancer drug Jemperli begins free supply in Korea
• by Eo, Yun-Ho Feb 14, 2023 05:49am

• Policy
• Paxlovid's expiration date has been extended
• by Lee, Hye-Kyung Feb 14, 2023 05:48am

• Company
• SK Plasma is exclusively selling Dacogen in Korea
• by Chon, Seung-Hyun Feb 14, 2023 05:48am

• Company
• The Paradox of Shingrix
• by Moon, sung-ho Feb 14, 2023 05:48am

• Opinion
• [Reporter’s View] Asthma drugs await reimb discussions
• by Eo, Yun-Ho Feb 14, 2023 05:48am

• Company
• “5 of 10 TNF-αis prescribed last year were adalimumab”
• by Kim, Jin-Gu Feb 14, 2023 05:48am

• Company
• Forxiga's patent war ended after eight years
• by Kim, Jin-Gu Feb 13, 2023 05:59am